RxDoctor Payments Data

Rahsaan Smith, MD

Cardiovascular Disease · Falls Church, VANPI 1952303950

Payments from drug & device makers

$872in general payments, 2019–2025

Across 19 payments — averaging $45.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$274
  • Astellas Pharma US Inc$198
  • Novartis$94
  • Medtronic$86
  • Cardiovascular Systems Inc.$48
  • AstraZeneca$36
  • plus $135 from 7 others

What the payments were for

  • Food & beverage$67477%
  • Education$19823%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$872 in reported general payments places this provider in the 35th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$175,139
Medicare patients
1,279
Services billed
2,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$206,834
EntrestoSacubitril/Valsartan100$132,926
JardianceEmpagliflozin70$84,516
XareltoRivaroxaban23$32,524
Repatha SureclickEvolocumab11$17,140
Metoprolol Succinate309$5,347
Atorvastatin Calcium263$2,932
Ezetimibe44$1,854
Rosuvastatin Calcium116$1,629
ClopidogrelClopidogrel Bisulfate110$1,422
Carvedilol162$1,295
Losartan Potassium102$989
Pravastatin Sodium44$982
Amiodarone Hcl15$842
Valsartan29$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$94$132,926100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →